|
Scimitar Equity covers a small universe of emerging therapeutic, device and diagnostic healthcare companies. The goal of our independent equity research is to provide analyst coverage and access to investors utilizing our timely recommendations. A credible third parties evaluation of the technology platform, clinical initiatives and unfolding developments at an emerging healthcare company is one key "sponsor" behind an investment decision. Timely definition and evaluation of milestone fulfillment are an important requisite in portfolio attraction. Insightful research, capitalization changes, valuation modeling, milestones definition and thorough comparable analysis assist in defining retention decisions. Scimitar's research formats and credibility as equity analysts has gained a significant following as investors seek comprehensive coverage from trustworthy sources for their investment consideration. Our "subscribing" clients research is widely distributed free-of-charge to all leading institutions, brokerage houses and high net worth individuals.
It is harder and harder for a company to obtain research coverage through I Bank's since the sell-side finds it increasingly difficult to bridge the gap between the high costs of its research operations and deteriorating commissions from its cash equity sales and trading business. Analyst compensation, retention and ultimately coverage have been driven down by trading volumes; particularly at firms that don't have investment-banking businesses. As a result, some investment banks have exited the research business altogether based purely on economic rationale. Scimitar Equity's "sponsored" compensation model is based on a "company paid" or "hard dollar" model which has offset the eroding "soft dollar" structures of brokerage houses. We also do not have any conflicts of brokerage trading, commission conflicts or investment banking operations.
Scimitar Equity's institutional outreach "opens the door" to access the "right" constituency of asset managers, high-net worth individuals, hedge funds, institutional and retail brokers that will "listen, purchase and hold" our recommendations for a defined period of time. During the past five (5) years our research product has been utilized by asset managers, institutional advisors, I-Banks, high-net worth individuals and other specialized investment professionals. Our staff capabilities are differentiated through twenty five (25) years of specialized experience in the sell-side and buy-side, venture/public investment fund communities and operating roles resulting in an extensive and valuable network.
|
